-
Brii Biosciences Launches Anti-COVID-19 Antibody Cocktail in China
•
China-based Brii Biosciences Ltd (HKG: 2137) announced the commercial launch in China of the anti-COVID-19 antibody cocktail amubarvimab + romlusevimab. The regimen represents a long-acting neutralizing antibody therapy against COVID-19. The first commercial batch of the antibodies was released today, marking an important milestone in the commercialization of the combination…
-
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Under FDA Review for NPC Treatment
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the Biologics License Application (BLA) for its programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) has been re-filed with and is under review by the US FDA. The filing covers two indications: Tuoyi’s use in combination with gemcitabine/cisplatin as a first-line treatment of…
-
I-Mab and MorphoSys License Drugs to HIBio in Global Oncology Deal
•
China-based I-Mab (NASDAQ: IMAB) detailed a licensing and equity investment deal between its German partner MorphoSys AG (FSE: MOR; Nasdaq: MOR) and U.S. biotech Human Immunology Biosciences, Inc. (HIBio). Under the agreement, MorphoSys granted HIBio global rights to develop and commercialize two drugs: the CD38 antibody felzartamab and the C5aR1…
-
Adicon Holdings and Guardant Health Partner on Genomic Profiling in China
•
China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, to bring Guardant’s comprehensive genomic profiling (CGP) tests to biopharmaceutical firms conducting clinical trials in China. The deal grants Adicon access to Guardant’s liquid biopsy technology, including the Guardant360,…
-
BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development
•
China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with compatriot company InnoRNA, a specialist in lipid-nanoparticle (LNP)-based delivery technology and mRNA drug discovery. The collaboration aims to leverage InnoRNA’s innovative platform for developing mRNA-based therapeutics. Agreement TermsUnder the deal, InnoRNA will receive an upfront…
-
PackGene and SineuGene Partner on ALS Gene Therapy Research
•
China-based PackGene has entered into another partnership with compatriot firm SineuGene. This time, the focus is on plasmid pharmaceutical research, adeno-associated virus (AAV) pharmaceutical research, AAV batch release testing, analytical methodology development, stability research, and more. The collaboration aims to support SineuGene’s lead pipeline candidate SG001, a genetic therapy under…
-
China Establishes Leadership Group to Combat Drug-Related Crimes
•
China’s State Council executive body released a notification regarding the establishment of a leadership group aimed at cracking down on crimes that could impact drug safety and endanger the public. The group will consist of several State Council deputies and leaders from key government agencies, including the National Medical Products…
-
Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push
•
Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100 million (USD 14.9 million) in a Series A financing round. The funding was led by Insight Capital and Tenaya Capital, with participation from Highthink Med. The proceeds will be used for the upgrade of its…
